Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG810

—

2c38203f-4bc6-5fab-aa19-5b48f5634d89

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.374
  • KRAS_SIGNALING_DN+0.350
  • APICAL_SURFACE+0.314
  • ALLOGRAFT_REJECTION+0.236
  • INFLAMMATORY_RESPONSE+0.216
  • TNFA_SIGNALING_VIA_NFKB+0.209
  • ESTROGEN_RESPONSE_LATE+0.187
  • ESTROGEN_RESPONSE_EARLY+0.144
  • MYOGENESIS+0.137
  • OXIDATIVE_PHOSPHORYLATION+0.127

Top 10 suppressed

  • PROTEIN_SECRETION-0.445
  • DNA_REPAIR-0.427
  • E2F_TARGETS-0.404
  • G2M_CHECKPOINT-0.399
  • MITOTIC_SPINDLE-0.398
  • UNFOLDED_PROTEIN_RESPONSE-0.389
  • MYC_TARGETS_V1-0.355
  • PI3K_AKT_MTOR_SIGNALING-0.320
  • MTORC1_SIGNALING-0.303
  • HEDGEHOG_SIGNALING-0.295

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG1154
mng-umap@100
——0.858
2SRR1473733
brain-umap@2
GTEX—0.858
3MNG466
mng-umap@100
——0.840
4SRR1488651
brain-umap@2
GTEX—0.839
5TCGA-95-A4VP-01A-21R-A262-07
lung-landscapes@6
—cohortA30.834
6SRR1500617
brain-umap@2
GTEX—0.831
7SRR1476186
brain-umap@2
GTEX—0.830
8TCGA-KQ-A41P-01A-12R-A33J-07
bladder-landscape@3
——0.829
9SRR1440962
brain-umap@2
GTEX—0.829
10SJEPD001523_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.828

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.374Cobimetinib— uncovered
KRAS_SIGNALING_DN0.350Remibrutinib— uncovered
APICAL_SURFACE0.314Temsirolimus— uncovered
ALLOGRAFT_REJECTION0.236Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.216Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.209Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.187Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.144Inavolisib— uncovered
MYOGENESIS0.137Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.127Remibrutinib— uncovered
APICAL_JUNCTION0.111Inavolisib— uncovered
COAGULATION0.107Binimetinib— uncovered
ANGIOGENESIS0.086Remibrutinib— uncovered
SPERMATOGENESIS0.069Inavolisib— uncovered
KRAS_SIGNALING_UP0.067Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.060Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.052Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.045Inavolisib— uncovered
BILE_ACID_METABOLISM0.017Inavolisib— uncovered
IL2_STAT5_SIGNALING0.012Idelalisib— uncovered